_edited_edited.png){kind=small}
Chimeric Antigen Receptor T-Cells
CAR-T Cell Therapy: Innovative Cancer Immunotherapy
CAR-T cell is a versatile living drug. A patient’s own T cells are genetically modified ex vivo to express Chimeric Antigen Receptors (CARs). Once reinfused into the patient’s body, CAR-T cells can recognize specific cancer markers and precisely destroy the tumor.
CAR-T therapy offers a personalized approach while minimizing damage to normal tissues, achieving improved efficacy and enhancing life quality.
_edited_edited.jpg)
CAR-108
CAR-108: New Strategy for Solid Tumors
CAR-108 was developed to overcome immune evasion in solid tumors. Its CAR specifically targets a molecule highly expressed across multiple tumor types. With a second-generation CAR design, CAR-108 sustains immune activity within the immunosuppressive tumor microenvironment.
CAR-108 significantly enhances its efficacy against solid tumors and offers broader therapeutic potential.